ArchPoint Investors - GLOBAL BLOOD THERAPEUTICS IN ownership

GLOBAL BLOOD THERAPEUTICS IN's ticker is GBT and the CUSIP is 37890U108. A total of 233 filers reported holding GLOBAL BLOOD THERAPEUTICS IN in Q4 2020. The put-call ratio across all filers is 1.21 and the average weighting 0.2%.

Quarter-by-quarter ownership
ArchPoint Investors ownership history of GLOBAL BLOOD THERAPEUTICS IN
ValueSharesWeighting
Q3 2022$11,490,000
+107.0%
168,725
-2.9%
4.69%
+113.3%
Q2 2022$5,552,000
-9.9%
173,765
-2.3%
2.20%
+3.6%
Q1 2022$6,159,000
+8.6%
177,789
-8.3%
2.12%
+26.2%
Q4 2021$5,672,000
+13.1%
193,789
-1.5%
1.68%
+12.1%
Q3 2021$5,014,000
-24.1%
196,789
+4.4%
1.50%
-32.9%
Q2 2021$6,602,000
-18.4%
188,508
-5.1%
2.24%
-2.3%
Q1 2021$8,095,000
-14.1%
198,650
-8.7%
2.29%
-12.0%
Q4 2020$9,420,000
-21.5%
217,5100.0%2.61%
-31.9%
Q3 2020$11,993,000
-0.2%
217,510
+14.3%
3.83%
-0.5%
Q2 2020$12,019,000
+24.4%
190,380
+0.7%
3.85%
+1.1%
Q1 2020$9,661,000
-34.9%
189,106
+1.3%
3.81%
-16.1%
Q4 2019$14,845,000
+95.8%
186,756
+19.5%
4.54%
+76.9%
Q3 2019$7,581,000
-8.0%
156,235
-0.3%
2.56%
-1.6%
Q2 2019$8,239,000
+9.9%
156,635
+10.6%
2.61%
+16.2%
Q1 2019$7,499,000
+30.8%
141,685
+1.4%
2.24%
+12.7%
Q4 2018$5,734,000
+16.6%
139,685
+7.9%
1.99%
+48.8%
Q3 2018$4,919,000
+22.5%
129,435
+45.7%
1.34%
+15.6%
Q2 2018$4,016,000
+1284.8%
88,840
+1380.7%
1.16%
+1261.2%
Q1 2018$290,000
+195.9%
6,000
+140.0%
0.08%
+174.2%
Q4 2017$98,0002,5000.03%
Other shareholders
GLOBAL BLOOD THERAPEUTICS IN shareholders Q4 2020
NameSharesValueWeighting ↓
Grace Capital 177,414$14,103,00011.50%
Fernwood Investment Management, LLC 258,012$20,509,0009.81%
Perceptive Advisors 5,865,726$466,266,0009.26%
ArchPoint Investors 186,756$14,845,0004.54%
STANSBERRY ASSET MANAGEMENT, LLC 115,638$9,192,0003.74%
Camber Capital Management LP 730,000$58,028,0002.95%
Profit Investment Management, LLC 46,873$3,726,0002.50%
Casdin Capital, LLC 300,000$23,847,0002.19%
SECTORAL ASSET MANAGEMENT INC 174,594$13,878,0002.07%
Corriente Advisors, LLC 40,000$3,180,0001.71%
View complete list of GLOBAL BLOOD THERAPEUTICS IN shareholders